Webinars

Most recent

• Large scale drug combination screening: Finding the needle in the haystack  In this on-demand webinar, learn about our cell panel screening platform and its application for large scale oncology drug combination screening.
• The race to market: Strategies for rapid therapeutic screening in immune cells In this on-demand webinar, Revvity’s Cell-Based Screening Team Leader Dr. Isabelle Nett and Taiho Pharmaceutical’s Scientist Dr. Yuki Kataoka discuss their experience in assessing therapeutic candidates' immunogenicity and characterizing therapeutic candidates quickly.
• Leveraging multiplatform cell-based screening for target ID In this on-demand webinar, Revvity’s Max Blanck demonstrates the power of using functional genomic and cell panel screening for improved target identification with a PARP inhibitor case study
• OncoSignature™ Long-term assay: Extending the reach of cell panel screens. In this on-demand webinar, Revvity’s Director of Cell-Based Screening David Sorrell introduces our OncoSignture™ Long-Term Assay service which enables the profiling of slower acting and epigenetic drugs over a 10-day period.
• CRISPR knockout guide RNA design for optimal function and specificity Emily Anderson, Principal Scientist at Horizon Discovery describes the development of the Dharmacon™ Edit-R™ CRISPR algorithm and the selection of predesigned guide RNAs for functional and highly specific knockouts.

• CRISPR screening to identify new drug targets in regulatory B cells and other immune cells
  As an example of how CRISPR screens can be used in primary immune cells, this webinar will cover in detail the development of arrayed CRISPR screens in regulatory B cells.
• CRISPR without the cut: Introducing CRISPRi - PAM-anchored transcriptional repression
  Learn about the development of the Dharmacon™ CRISPRmod™ CRISPR interference platform, designed specifically to be used with synthetic sgRNA.
• CRISPR Single-Cell Screening Drives Biological Discovery 
  During this webinar Horizon's Dr. Carlos le Sage presents data showing how our CRISPRsc screening platform offers a streamlined approach to elucidating valuable and intriguing biological information that is critical to resolving complex biological questions.
• Expression of Fab-based Fusion Proteins using HD-BIOP3 GS Null CHO K1 cell line
  Sang-hoon Cha professor at Kangwon National University presents at BPI Asia Virtual 2021.

• Expression of a bispecific antibody using a CHO-K1 cell line
  Jay Sinha from Incyte Corp presents at BPI West Virtual 2021.

• A Conversation with Jennifer Doudna, 2020 Nobel Laureate Watch Jennifer Doudna in a candid “fireside chat” with several of her colleagues and friends to discuss the pivotal research that led to the award and celebrate a truly groundbreaking scientist.

• CRISPR screening in primary human T cells: Extending cell type capabilities Sign up for this well to learn about human T cell gene editing, donor variability in T cells CRISPR screening and NGS data analysis for genetic screenings.
• Tackling disease with iPSCs and genome editing In this GEN webinar, we provide a field overview of how iPSCs, coupled with genome editing, hold the potential to expand our understanding of human diseases further and facilitate the development of new therapies.
• Advancing cancer drug development using 2D and 3D cell panel screens The clinical-relevance of cell panel screens can be enhanced by integrating robust, high throughput methods for screening in three-dimensional models, including cell line-derived spheroids and patient-derived organoids. Find out more by signing up for this webinar.
• Gene editing and RNAi in primary human immune cells Gene manipulation studies in primary human immune cells can answer important biological questions within a clinically relevant cellular context. Learn about several gene editing or modulation tools, including CRISPRko, RNAi and base editing, to modify various primary human immune cell types.
• Improving cell-based assays and their future in drug discovery Topics covered will include 3D in vitro models; complex co-culture assays using patient samples; iPSCs; imaging as a method for understanding the impact of a therapeutic; the use of functional genomic screens to aid drug discovery; and in vitro models to support the 3Rs.
• Leveraging advances in predesigned synthetic sgRNAs for highly functional and specific CRISPR-Cas9 gene knockout Synthetic guide RNAs are amenable to chemical modifications, eliminate time-consuming steps of cloning, do not have the inherent immune response and cytotoxicity, and can be readily delivered into cells for high-throughput arrayed screening applications.
• High-throughput genome-wide RNAi screens: Insights from the Sheffield RNAi Screening Facility This webinar will provide an overview of high-throughput RNAi screening from the perspective of a dedicated RNAi screening facility.

Webinar series

• CHOSOURCE in biotherapeutic production, a three-part customer presentation series
  Join Dr Allyn Spear (Elanco Animal Health), Michael Cullivan (Jounce Therapeutics) and Jeffrey McGrew (Just-Evotech Biologics) as they share how their teams have used Horizon's CHOSOURCE in their biotherapeutic workflows.

All webinars

• A virtual workshop for precise HDR-mediated genome engineering with CRISPR-Cas9 The use of CRISPR-Cas9 to create targeted double-strand breaks in genomic DNA has greatly simplified strategies for precise gene editing using the homology-directed repair (HDR) mechanism.
• Addressing the variability of molecular assays Horizon Discovery is a translational company and we have expertise in genome editing, discovery services, and diagnostic reagents.
• Analyzing the combination effects of multi-drug interventions The increasing size and complexity of data sets from combination studies represent a major challenge in the drug discovery process.
• CRISPR engineered human cell lines and types of genomic modifications Explore through case studies the types of modifications that can be made with CRISPR-Cas9 in human cell lines
• CRISPR screening: From target selection to patient stratification In a remarkably short time since its development, high-throughput CRISPR screening has revolutionized functional genomics and drug discovery
• CRISPR screening in primary human T cells: Extending cell type capabilities Genetic screens are powerful tools to interrogate cell response to drug treatment as well as microenvironment perturbations.
• CRISPR screening: the What, Why, and How... CRISPR–Cas9 mediated genome editing provides a highly efficient way to probe gene function.
• CRISPRa tools for transcriptional activation studies The CRISPR-Cas9 system has been adapted to upregulate any gene in its endogenous context, enabling overexpression experiments.
• Exploring inducible systems to inactivate wildtypes This webinar will describe the level of knockdown that can be achieved with degron-tagged CRISPR interference proteins, how best to deploy dox-inducible Cas9, and various approaches to delete wild-type alleles of genes so as to replace them with inactive alleles that could be applied at scale.
• High-throughput CRISPR-Cas9 genome engineering in primary T cells Learn how to optimize CRISPR-Cas9 gene editing in primary T cells using RNPs, and how this is being employed to understand HIV pathogenesis
• How CRISPR-Cas9 screening will revolutionize your drug development programs A powerful tool for drug target ID and validation, understanding drug mechanisms of action, and patient stratification.
• How to use CRISPR-Cas9 for knockout, knock-in, and gene activation The rapid adoption and ease of use of CRISPR-Cas9 has driven the development of applications for gene knockout, precise gene editing, and transcriptional regulation.
• How to validate and verify the accuracy of your clinical laboratory procedures In the webinar we will discuss the latest developments surrounding the FDA and LDTs and will present examples of how HDx Reference Standards could help your laboratory improve the accuracy of your assay.
• Large scale drug combination screening: Finding the needle in the haystack  In this on-demand webinar, learn about our cell panel screening platform and its application for large scale oncology drug combination screening.
• Leveraging multiplatform cell-based screening for target ID In this on-demand webinar, Revvity’s Max Blanck demonstrates the power of using functional genomic and cell panel screening for improved target identification with a PARP inhibitor case study
• OncoSignature™ Long-term assay: Extending the reach of cell panel screens. In this on-demand webinar, Revvity’s Director of Cell-Based Screening David Sorrell introduces our OncoSignture™ Long-Term Assay service which enables the profiling of slower acting and epigenetic drugs over a 10-day period.
• Phenotypic CRISPR screening beyond cell viability to study complex genetic interactions CRISPR screening, whether using knockout, activation, or inhibition approaches, have become essential tools for drug discovery
• Power up CRISPRi and CRISPRa tools for genome-wide screening Ben joined Horizon in 2013 to expand and develop Horizon’s functional genomic screening capability and to lead a major research alliance in synthetic lethal target discovery.
• Resolving ambiguity in target ID screens CRISPR Cas9 based essentiality profiling The CRISPR–Cas9 system can be used to disrupt specific genes leading to genetic knockouts.
• Systematic application of the CRISPR toolkit View our webinar on Dual CRISPRi and CRISPRa screening which can power up your drug discovery and development programs, improving your rate of target discovery:
• The effect of formalin on clinical diagnostics The use of formalin fixative stems from its ability to cross-link proteins, however, it has also been reported to induce methylol modifications and acid-mediated hydrolysis which can confound genotyping analysis. Similarly, variability in the fixation time, delay of fixation and type of fixation effect tumor biopsies and subsequent sequencing.
• The race to market: Strategies for rapid therapeutic screening in immune cells In this on-demand webinar, Revvity’s Cell-Based Screening Team Leader Dr. Isabelle Nett and Taiho Pharmaceutical’s Scientist Dr. Yuki Kataoka discuss their experience in assessing therapeutic candidates' immunogenicity and characterizing therapeutic candidates quickly.
• Understanding and controlling for sample and platform biases in NGS assays In this webinar, we will focus on next-generation sequencing and discuss: the effect of formalin treatment on molecular protocols and how it can be controlled, how to select the sequencing platform most appropriate for your sample, evaluation of whether structural variants are being detected by your assay and how Reference Standards can be used in each validation parameter.
• Using reference standards to validate your NGS oncology workflow We are currently at an exciting precipice in clinical oncology management, where an increased rate of biomarker identification is driving the development of new targeted therapies, coupled with advances in sequencing technology capability.